Bazedoxifene Acetate
FDA-approved product (tablet, oral).
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Postmenopausal osteoporosis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Selective estrogen receptor modulators
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA51.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli43.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae29.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis61.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Bazedoxifene Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- AfamelanotideExisting use: Erythropoietic protoporphyria65.1% AI-predicted activityagainst MRSA23 registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives64.9% AI-predicted activityagainst MRSALab records exist50+ registered studies
- Imatinib MesylateExisting use: Acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 7 more64.9% AI-predicted activityagainst MRSA50+ registered studies
- Naldemedine TosylateExisting use: Constipation, Constipation disorder64.8% AI-predicted activityagainst MRSA1 registered study
- Vorapaxar SulfateExisting use: Myocardial infarction, Peripheral arterial disease, Recurrent thrombophlebitis and 1 more64.8% AI-predicted activityagainst MRSA15 registered studies
- Rimegepant SulfateExisting use: Migraine disorder64.7% AI-predicted activityagainst MRSA50+ registered studies
- Terlipressin AcetateExisting use: Hepatorenal syndrome, Kidney failure, Renal insufficiency64.6% AI-predicted activityagainst MRSA7 registered studies
- Bremelanotide AcetateExisting use: Mental or behavioural disorder, Physiological sexual disorder, Sexual dysfunction64.5% AI-predicted activityagainst MRSA1 registered study
- Tazemetostat HydrobromideExisting use: Follicular lymphoma, Neoplasm, Sarcoma64.4% AI-predicted activityagainst MRSA3 registered studies
- Isavuconazonium SulfateExisting use: Aspergillosis, Mucormycosis64.3% AI-predicted activityagainst MRSA50+ registered studies
- Nirogacestat HydrobromideExisting use: Gastrointestinal desmoid tumor64.2% AI-predicted activityagainst MRSA1 registered study
- Prasugrel HydrochlorideExisting use: Acute coronary syndrome, Hemorrhage, Intermediate coronary syndrome and 1 more64.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women
NCT00242710 · start 2005-09
Registered record
- Registry ID
- NCT00242710
- Conditions
- Endometrial Hyperplasia; Osteoporosis
- Interventions
- Bazedoxifene/Conjugated Estrogen; Bazedoxifene/Conjugated Estrogen; CE 0.45 mg/MPA 1.5mg; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2005-09
- Completion
- 2008-09
- Enrolment
- 1,083
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEndometrial Hyperplasia; OsteoporosisInterventionBazedoxifene/Conjugated Estrogen; Bazedoxifene/Conjugated Estrogen; CE 0.45 mg/MPA 1.5mg; PlaceboPhasePhase 3Registry statusCompletedStudy Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis.
NCT00238745 · start 2003-08
Registered record
- Registry ID
- NCT00238745
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- Bazedoxifene; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2003-08
- Completion
- 2007-03
- Enrolment
- 375
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostmenopausal OsteoporosisInterventionBazedoxifene; PlaceboPhasePhase 2Registry statusCompletedStudy Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women
NCT00675688 · start 2002-04
Registered record
- Registry ID
- NCT00675688
- Conditions
- Endometrial Hyperplasia; Osteoporosis
- Interventions
- Bazedoxifene/Conjugate Estrogens (CE); Raloxifene; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2002-04
- Completion
- 2006-01
- Enrolment
- 3,544
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEndometrial Hyperplasia; OsteoporosisInterventionBazedoxifene/Conjugate Estrogens (CE); Raloxifene; PlaceboPhasePhase 3Registry statusCompletedStudy Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women
NCT00205777 · start 2001-12
Registered record
- Registry ID
- NCT00205777
- Conditions
- Osteoporosis
- Interventions
- Bazedoxifene Acetate; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2001-12
- Completion
- 2010-09
- Enrolment
- 7,609
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOsteoporosisInterventionBazedoxifene Acetate; PlaceboPhasePhase 3Registry statusCompletedStudy Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal Women
NCT00481169 · start 2001-07
Registered record
- Registry ID
- NCT00481169
- Conditions
- Osteoporosis
- Interventions
- Bazedoxifene Acetate (TSE-424)
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2001-07
- Completion
- 2004-09
- Enrolment
- 1,742
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOsteoporosisInterventionBazedoxifene Acetate (TSE-424)PhasePhase 3Registry statusCompleted